Myeloma 2018 | Where in the treatment sequence should CAR T-cells be used for myeloma?

Andrew Spencer, David Siegel and Ravi Vij

The experts at the Myeloma 2018 meeting in San Diego, CA, discussed the successes, challenges and future outlook for CAR T-cells in multiple myeloma (MM), considering the question of where CAR T-cells will be best placed in therapy sequencing. Exploring this intriguing question, David Siegel, MD, PhD, of the John Theurer Cancer Center, Hackensac, NJ, chairs a dicussion with Andrew Spencer, MBBS, FRACP, FRCPA, DM, of Alfred Hospital, Monash University, Melbourne, Australia, and Ravi Vij, MD, MBA, of Washington University Medical School, St. Louis, MO.

Share this video